Young Kwang Chae, MD, MPH, MBA, an associate professor of medicine at Northwestern Medicine Feinberg School of Medicine, discusses using crizotinib (Xalkori) to treat MET-positive patients with non—small cell lung cancer (NSCLC).

The current National Comprehensive Cancer Network guidelines mention 

 exon 14 skipping mutation, explains Chae. Crizotinib, which was granted a breakthrough designation by the FDA in May 2018 for the treatment of patients with metastatic NSCLC with 

 exon 14 alterations who progress after receiving platinum-based chemotherapy.

Early-phase data for crizotinib, according to Chae, shows a clean waterfall plot with tolerable toxicity and positive efficacy. The data appear promising and the drug will likely appear as a frontline treatment in the future for patients with 

Videos

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Young Kwang Chae, MD, MPH, MBA

Articles

Dr. Chae on Using Crizotinib to Treat MET+ NSCLC